OCS Valuation

Oculis Holding AG

Add to Watchlist

Advanced Chart

17.900

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

OCS Relative Valuation

OCS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OCS is overvalued; if below, it's undervalued.

Historical Valuation

Oculis Holding AG (OCS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1275.84 is considered Overvalued compared with the five-year average of -5.03. The fair price of Oculis Holding AG (OCS) is between 3.34 to 12.40 according to relative valuation methord. Compared to the current price of 17.90 USD , Oculis Holding AG is Overvalued By 44.38%.

Relative Value

Fair Zone

3.34-12.40

Current Price：17.90

44.38%

Overvalued

-8.13

Trailing

Forward

-7.70

EV/EBITDA

Oculis Holding AG. (OCS) has a current EV/EBITDA of -7.70. The 5-year average EV/EBITDA is -5.40. The thresholds are as follows: Strongly Undervalued below -13.43, Undervalued between -13.43 and -9.41, Fairly Valued between -1.38 and -9.41, Overvalued between -1.38 and 2.64, and Strongly Overvalued above 2.64. The current Forward EV/EBITDA of -7.70 falls within the Historic Trend Line -Fairly Valued range.

-7.74

EV/EBIT

Oculis Holding AG. (OCS) has a current EV/EBIT of -7.74. The 5-year average EV/EBIT is -4.72. The thresholds are as follows: Strongly Undervalued below -11.38, Undervalued between -11.38 and -8.05, Fairly Valued between -1.40 and -8.05, Overvalued between -1.40 and 1.93, and Strongly Overvalued above 1.93. The current Forward EV/EBIT of -7.74 falls within the Historic Trend Line -Fairly Valued range.

1275.84

Oculis Holding AG. (OCS) has a current PS of 1275.84. The 5-year average PS is 469.41. The thresholds are as follows: Strongly Undervalued below -337.98, Undervalued between -337.98 and 65.71, Fairly Valued between 873.10 and 65.71, Overvalued between 873.10 and 1276.79, and Strongly Overvalued above 1276.79. The current Forward PS of 1275.84 falls within the Overvalued range.

0.00

P/OCF

Oculis Holding AG. (OCS) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.54. The thresholds are as follows: Strongly Undervalued below -9.48, Undervalued between -9.48 and -6.01, Fairly Valued between 0.94 and -6.01, Overvalued between 0.94 and 4.41, and Strongly Overvalued above 4.41. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Oculis Holding AG. (OCS) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.87. The thresholds are as follows: Strongly Undervalued below -11.59, Undervalued between -11.59 and -7.23, Fairly Valued between 1.49 and -7.23, Overvalued between 1.49 and 5.85, and Strongly Overvalued above 5.85. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Oculis Holding AG (OCS) has a current Price-to-Book (P/B) ratio of 4.63. Compared to its 3-year average P/B ratio of 3.65 , the current P/B ratio is approximately 26.83% higher. Relative to its 5-year average P/B ratio of 2.88, the current P/B ratio is about 60.50% higher. Oculis Holding AG (OCS) has a Forward Free Cash Flow (FCF) yield of approximately -6.76%. Compared to its 3-year average FCF yield of -10.77%, the current FCF yield is approximately -37.22% lower. Relative to its 5-year average FCF yield of -10.38% , the current FCF yield is about -34.87% lower.

4.63

P/B

Median3y

3.65

Median5y

2.88

-6.76

FCF Yield

Median3y

-10.77

Median5y

-10.38

Competitors Valuation Multiple

The average P/S ratio for OCS's competitors is 805.28, providing a benchmark for relative valuation. Oculis Holding AG Corp (OCS) exhibits a P/S ratio of 1275.84, which is 58.43% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Praxis Precision Medicines Inc

Oric Pharmaceuticals Inc

Loss

938.21M

SYRE.O

Spyre Therapeutics Inc

Loss

1.02B

LENZ.O

LENZ Therapeutics Inc

Performance Decomposition

Market capitalization of OCS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of OCS in the past 1 year is driven by Unknown.